GlassScriptPhysician profile
Stephen Chruscicki
NPI 1871157289
$5,955.70
in general payments reported to CMS, 2019-2025
23 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $147 · 2023: $2,271 · 2024: $2,363 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,790 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,789.55 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $990.26 | 2023-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $916.74 | 2023-2024 | Jardiance |
| Pfizer INC. | $593.96 | 2023-2025 | |
| Novo Nordisk INC | $584.53 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $452.30 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $442.16 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $399.43 | 2023-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $304.67 | 2024-2025 | Airsupra, Breztri, Lokelma |
| Glaxosmithkline, LLC. | $251.16 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $235.67 | 2023-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $147.41 | 2023-2025 | Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $131.07 | 2023-2024 | Trintellix |
| Ardelyx, INC. | $100.98 | 2024-2025 | Ibsrela |
| Antares Pharma, INC. | $71.38 | 2024-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $62.73 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $56.43 | 2024 | (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $48.72 | 2024 | Verquvo |
| Currax Pharmaceuticals LLC | $45.32 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Lilly USA, LLC | $37.75 | 2024 | Zepbound, Jardiance, Mounjaro |
| Halozyme INC | $26.31 | 2023 | |
| Esperion Therapeutics, INC. | $21.11 | 2023 | Nexletol |
| Vivus LLC | $20.45 | 2023 | Qsymia |
| Phathom Pharmaceuticals, INC. | $15.16 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Chruscicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.